Good morning and welcome to Markets Desk.
Roche is making headlines with a rare double approval from the FDA, clearing Wilserdly — a combination therapy with everolimus — for advanced breast cancer, alongside Gazyva for chronic kidney disease. Dual approvals in a single announcement are uncommon, and this meaningfully broadens Roche's commercial pipeline across two high-burden disease categories.
Shifting to tech, MongoDB is acquiring analytics firm Firebolt in a deal aimed squarely at the AI infrastructure race. The purchase price was not disclosed, though reports suggest it came in well below Firebolt's prior valuation of one-point-four billion dollars. MongoDB is betting that real-time analytics capability will be essential as enterprises build AI agents that need to act on data in milliseconds rather than minutes.
And on the energy side, crude oil is pushing higher, with December West Texas Intermediate up nearly one percent on the session. The catalyst is geopolitical — escalating tensions around a potential US-Iran conflict are raising concerns about supply disruption in a market that was already watching OPEC discipline closely. Gasoline futures are moving in sympathy.
That's the tape. Markets Desk, signing off the floor.
